Hypoparathyroidism Clinical Trial
Official title:
Physiologic Regulation of FGF-23
This study will explore the regulation of fibroblast growth factor-23 (FGF-23). It is a
hormone recently identified as a regulator of the blood levels of phosphorus and vitamin D,
both of which are essential for overall health and especially important for bone health. The
parathyroid hormone (PTH) regulates phosphorus and calcium, but people with
hypoparathyroidism or pseudohypoparathyroidism do not have sufficient PTH action. There are
genetic diseases that influence FGF-23, causing abnormal metabolism of phosphorus and vitamin
D, thus affecting the bones. Also, there are rare tumors that may cause overproduction of
FGF-23 causing debilitating bone disease.
Patients ages 18 and older who have low PTH levels, or are resistant to PTH action, and take
calcitriol and calcium supplements, who are not pregnant, and who do not have kidney
disorders may be eligible for this study. During the 4-day study, patients will be provided
with a controlled diet that has a lower than usual phosphorus content. On day 1, patients
will be admitted to the NIH Clinic Center and undergo blood and urine tests to measure
calcium, phosphorus, vitamin D, and FGF-23. They will continue with their regular medicine
for hypoparathyroidism. On that day and throughout the study, patients will fast from 10:00
p.m. to 8:00 a.m. the following day. On day 2, patients will continue fasting until 4:00 p.m.
A tube will be placed in the vein of each arm: one for drawing blood and the other for
infusing calcium. Just one intravenous (IV) line will be used on the other days. Patients
will receive calcium chloride for 8 hours, at a dose carefully monitored by a machine. The
purpose is to bring the blood calcium level to the high normal range or just above. Blood and
urine samples will be collected periodically, to check for effects of calcium chloride on
FGF-23 and PTH. On days 3 and 4, patients will not take calcitriol and calcium but will
receive injections of PTH, under the skin, two times each day. On day 3, blood and urine
samples will be again be collected for analysis. On day 4, patients will receive one dose of
calcitriol by IV. The total amount of blood drawn during this study will be about 5 ounces.
Vitamin D and phosphate are central to normal mineral homeostasis and important in many
physiologic functions including skeletal integrity. For several decades parathyroid hormone
(PTH) has been recognized as a central regulator of serum vitamin D and phosphate levels.
Recently, FGF-23 has been identified as central in the regulation of the metabolism of
vitamin D and serum phosphorus. The organ primarily responsible for the physiologic
production of FGF-23 appears to be the skeleton. The study of FGF-23 metabolism and its
direct effect on mineral metabolism is confounded by the classic endocrine feedback loops
that exist among serum calcium, phosphorus, 1,25-(OH)2-vitamin D (1,25-D), and PTH. It is
possible that any of these (phosphorus, calcium, 1,25-D, and/or PTH) are important in the
regulation of serum FGF-23. The goal of this study is to identify what factors regulate serum
FGF-23.
To overcome the confounding effect of PTH, we will study patients deficient in PTH
(hypoparathyroidism) or resistant to PTH at the kidney (pseudohypoparathyroidism type 1B,
PHP1B). The kidney is one of the primary organs responsible for regulating serum phosphorus
and generating 1,25-D. It is the target of PTH and FGF-23. While patients with PHP1B are
resistant to the action of PTH at the kidney, they are sensitive to the action of PTH at the
bone, the tissue that produces FGF-23. Physiologic manipulation of the serum phosphorus,
1,25-D, calcium, and PTH in subjects with hypoparathyroidism or PHP1B will allow for a nearly
complete dissection of the factors that are potential regulators of serum FGF-23.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03364738 -
Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism
|
Phase 3 | |
Active, not recruiting |
NCT00856401 -
ADD-ON Study to Existing Hypoparathyroidism Studies
|
Phase 3 | |
Completed |
NCT05043584 -
Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions
|
N/A | |
Completed |
NCT03728959 -
Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.
|
N/A | |
Not yet recruiting |
NCT06445036 -
Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism.
|
||
Recruiting |
NCT05556629 -
A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
|
||
Terminated |
NCT00395538 -
Effects of PTH Replacement on Bone in Hypoparathyroidism
|
Phase 3 | |
Completed |
NCT02910466 -
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
|
Phase 4 | |
Completed |
NCT00001304 -
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
|
Phase 2 | |
Completed |
NCT04569604 -
QoL and Cognitive Function in Patients With Hypoparathyroidism
|
||
Completed |
NCT06449729 -
Endocrine Determinants of Renal Function in Patients With Hypoparathyroidism
|
||
Completed |
NCT03747029 -
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
|
||
Completed |
NCT05684029 -
Near-Infrared Autofluorescence With PTH Test Strip as an SOP of Parathyroid in Thyroid Surgery
|
||
Not yet recruiting |
NCT06419270 -
Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
|
||
Completed |
NCT00473265 -
Bone Properties in Hypoparathyroidism: Effects of PTH
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05328076 -
Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography
|
||
Completed |
NCT03150108 -
Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT04059380 -
Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY)
|
||
Active, not recruiting |
NCT05965167 -
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
|
Phase 1/Phase 2 | |
Recruiting |
NCT02986607 -
Corticosteroid Rhythms in Hypoparathyroid Patients
|
Early Phase 1 |